Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
With
Tanabe Pharma Corporation
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with chronic obstructive pulmonary disease
Current smoker or ex-smoker
30 to 80% of predicted FEV1 after inhalation of short acting beta stimulant
You may not be if
Patients with poorly controlled COPD
Patients who need for long-term oxygen therapy
Patients who have concurrent respiratory diseases such as asthma, diffuse panbronchiolitis, congenital sinobronchial syndrome, bronchiolitis obliterans, bronchiectasis, active tuberculosis, pneumoconiosis, pulmonary lymph vascular myoma, which are considered to affect the evaluation
Clareo Health | Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)
